Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Clinical trial NCT05660993 · UNKNOWN
Trial details
- NCT number
- NCT05660993
- Sponsor
- National Research Center for Hematology, Russia
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-19
- Primary completion
- 2025-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.